Magnetic resonance angiography with blood-pool contrast agents: future applications.
Blood pool agents remain in the intravascular space for a longer time period. Therefore the optimal imaging window for vascular structures is widened to about 30 minutes. Gadofosveset trisodium (Vasovist, Bayer Schering Pharma AG, Berlin, Germany) is the first blood-pool contrast agent approved in Europe for contrast-enhanced magnetic resonance angiography (MRA) of vessels in the abdomen, pelvis and lower extremity in adults. Other possible applications of blood-pool agents are now being considered, such as assessment of venous thromboembolism, coronary artery disease or sinus venous thrombosis. Perfusion MR imaging holds promise for detecting lung perfusion defects with higher spatial resolution and reduced scan time compared with radionuclide scintigraphy. In coronary artery disease, blood-pool agents enable a substantial increase in the quality of coronary artery imaging. Quantitative myocardial perfusion and myocardial viability seem to be possible, although modifications in protocols and sequence design are necessary for optimal results. Other novel applications of blood-pool agents include monitoring of inflammatory changes in systemic lupus erythematosus and evaluation of tumour invasion into lymph nodes and more reliable assessment of cerebral venous and sinus thombosis.
Fink
Christian
C
University Hospitals, Grosshadern, Munich, Germany.
Goyen
Mathias
M
Lotz
Joachim
J
D003287:Contrast Media; D003327:Coronary Disease / Q000175:diagnosis; D005544:Forecasting; D005682:Gadolinium; D006801:Humans; D018810:Magnetic Resonance Angiography / Q000639:trends*; D009942:Organometallic Compounds; D013923:Thromboembolism / Q000175:diagnosis; D014652:Vascular Diseases / Q000175:diagnosis*; D020246:Venous Thrombosis / Q000175:diagnosis
D003287:Contrast Media; D009942:Organometallic Compounds; D005682:Gadolinium; C109932:gadofosveset trisodium